BIOBOHEMIA
This site uses cookies to provide you with a more responsive and personalized service. By using this site you agree to the Privacy Policy and Terms of Use.
I accept
Close

Novel Antigen Compositions

Produced by Antigenic Essence Technology
For the Treatment of Oncological Diseases by Vaccination

Novel Antigen Compositions
Produced by Antigenic Essence Technology For the Treatment of Oncological Diseases by Vaccination

See our latest scientific paper
Lokhov, P.G.; Lichtenberg, S.; Balashova, E.E. Changing Landscape of Cancer Vaccines—Novel Proteomics Platform for New Antigen Compositions. Int. J. Mol. Sci. 2022, 23, 4401.

The creation of cancer vaccines is a constant priority for research and biotechnology. Therefore, the emergence of any new technology in this field is a significant event, especially because previous technologies have not yielded results. Recently, the development of a cancer vaccine has been complemented by a new proteomics technology platform that allows the creation of antigen compositions known as antigenic essences.
Antigenic essence comprises a target fraction of cellular antigens, the composition of which is precisely controlled by peptide mass spectrometry and compared to the proteomic footprint of the target cells to ensure similarity. This proteomics platform offers potential for a massive upgrade of conventional cellular cancer vaccines. Antigenic essences have the same mechanism of action, but without the disadvantages, and with notable advantages such as precise targeting of the immune response, safety, controlled composition, improved immunogenicity, addressed MHC restriction, and extended range of vaccination doses. The present paper calls attention to this novel platform, stimulates discussion of the role of antigenic essence in vaccine development, and consolidates academic science with biotech capabilities. A brief description of the platform, list of cellular cancer vaccines suitable for the upgrade, main recommendations, limitations, and legal and ethical aspects of vaccine upgrade are reported here.
See our latest
scientific paper
Lokhov, P.G.; Lichtenberg, S.; Balashova, E.E. Changing Landscape of Cancer Vaccines—Novel Proteomics Platform for New Antigen Compositions. Int. J. Mol. Sci. 2022, 23, 4401.
The creation of cancer vaccines is a constant priority for research and biotechnology. Therefore, the emergence of any new technology in this field is a significant event, especially because previous technologies have not yielded results. Recently, the development of a cancer vaccine has been complemented by a new proteomics technology platform that allows the creation of antigen compositions known as antigenic essences.
Antigenic essence comprises a target fraction of cellular antigens, the composition of which is precisely controlled by peptide mass spectrometry and compared to the proteomic footprint of the target cells to ensure similarity. This proteomics platform offers potential for a massive upgrade of conventional cellular cancer vaccines. Antigenic essences have the same mechanism of action, but without the disadvantages, and with notable advantages such as precise targeting of the immune response, safety, controlled composition, improved immunogenicity, addressed MHC restriction, and extended range of vaccination doses. The present paper calls attention to this novel platform, stimulates discussion of the role of antigenic essence in vaccine development, and consolidates academic science with biotech capabilities. A brief description of the platform, list of cellular cancer vaccines suitable for the upgrade, main recommendations, limitations, and legal and ethical aspects of vaccine upgrade are reported here.
About our company
and technology
Biobohemia, Inc. is a biotechnology company focused on development of cancer vaccines.

Biobohemia's lead technology is cell Antigenic Essence production via proteomics and cell culture technology, and which is a deep upgrade of cellular cancer vaccines. Antigenic essence technology is the revitalization of cellular vaccination, as antigenic essence exhibits all the identifying properties of cancer cells while also allowing for control of composition, purification from ballast substances (cellular 'noise'), and evasion of MHC restrictions. Therefore, antigenic essence technology allows upgading of already discovered cellular compositions, as well as creation new ones.

Our antigenic essence technology platform is behind the development of the potential candidates for cancer vaccine, under the brand name SANTAVACTM, that can be tuned against virtually any solid cancer. Our company is progressing the development of both prevention and therapeutic SANTAVACTM vaccines.
About our company
and technology
Biobohemia, Inc. is a biotechnology company focused on development of cancer vaccines.

Biobohemia's lead technology is cell Antigenic Essence production via proteomics and cell culture technology, and which is a deep upgrade of cellular cancer vaccines. Antigenic essence technology is the revitalization of cellular vaccination, as antigenic essence exhibits all the identifying properties of cancer cells while also allowing for control of composition, purification from ballast substances (cellular 'noise'), and evasion of MHC restrictions. Therefore, antigenic essence technology allows upgading of already discovered cellular compositions, as well as creation new ones.

Our antigenic essence technology platform is behind the development of the potential candidates for cancer vaccine, under the brand name SANTAVACTM, that can be tuned against virtually any solid cancer. Our company is progressing the development of both prevention and therapeutic SANTAVACTM vaccines.